Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease

This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> (MAP), long considered a putative cause, would favorably affect Crohn’s disease. A double-blind multice...

Descrizione completa

Dettagli Bibliografici

Autori principali:	David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-07-01
Serie:	Antibiotics
Soggetti:	RHB-104 Crohn’s disease <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> clinical trial clarithromycin rifabutin
Accesso online:	https://www.mdpi.com/2079-6382/13/8/694
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!